You are here: Industry Insights > AstraZeneca

News List

AstraZeneca’s Imfinzi and Tremelimumab with Chemotherapy Demonstrated Overall Survival Benefit in Trial for Non-Small Cell Lung Cancer americanpharmaceuticalreview
May 08, 2021
The POSEIDON trial was a Phase III trial of AstraZeneca’s Imfinzi (durvalumab) plus platinum-based chemotherapy or Imfinzi, tremelimumab and chemotherapy versus chemotherapy alone in the 1st-line treatment of patients with Stage IV (metastatic) ...
Alchemab to collaborate with AstraZeneca on prostate cancer research pharmatimes
May 07, 2021
Cambridge-based biotech company Alchemab has announced a new collaboration with British pharma AstraZeneca (AZ), aiming to accelerate research for prostate cancer.
AstraZeneca Announces First Quarter 2021 Results americanpharmaceuticalreview
May 06, 2021
AstraZeneca delivered robust revenue growth of 15% (11% at CER) in the quarter to $7,320m; excluding the contribution from the pandemic COVID-19 vaccine, revenue growth increased by 11% (7% at CER) to $7,045m.
MHRA reports 41 blood clot cases after use of AstraZeneca Covid-19 vaccine pharmaceutical-technology
May 06, 2021
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has reported an additional 41 cases of rare blood clots in people who have received doses of AstraZeneca’s Covid-19 vaccine.
FDA approves AstraZeneca’s Farxiga for chronic kidney disease treatment pharmaceutical-technology
May 06, 2021
The US Food and Drug Administration (FDA) has approved AstraZeneca’s Farxiga (dapagliflozin) for treating chronic kidney disease (CKD) in patients who are at the risk of progression with and without type-2 diabetes.
Over a quarter of UK adults have received both COVID-19 vaccine doses pharmatimes
April 28, 2021
The Department of Health and Social Care (DHSC) has announced that over a quarter of adults in the UK have now received both doses of a COVID-19 vaccine in the latest vaccination milestone.
CHMP suggests AstraZeneca and Merck’s selumetinib for paediatric patients pharmaceutical-technology
April 28, 2021
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended AstraZeneca and Merck’s (MSD) selumetinib for conditional marketing authorisation in the EU for treating children aged three years and ...
Positive topline results for nirsevimab in RSV pharmatimes
April 27, 2021
Sanofi and AstraZeneca’s (AZ) monoclonal antibody (mAb) nirsevimab reached its primary endpoint in a Phase III trial, demonstrating protection against respiratory syncytial virus disease (RSV) in healthy infants.
First patients dosed with Fasenra in three dermatology trials europeanpharmaceuticalreview
April 26, 2021
With the addition of the new dermatology trials, Fasenra is now being evaluated in nine different indications associated with eosinophilic immune dysfunction.
Wuxi Strives to Build a World-class Biomedical Industry Chain prnasia
April 23, 2021
From April 21 to 23, the 2021 Taihu Bay Future Healthcare Conference was held in Wuxi, China. More than 160 experts including Hejie, Fan Chunhai and many other academicians carried out forward-looking, authoritative, and predictive exchanges and ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page